Zymeworks (ZYME) Common Equity (2021 - 2026)

Zymeworks' Common Equity history runs 6 years deep, the most recent figure standing at $163.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 49.66% year-over-year to $163.6 million; the TTM figure through Mar 2026 stood at $163.6 million (down 49.66% YoY), while the FY2025 annual figure was $268.5 million, down 20.74% from the prior year.
• Common Equity came in at $163.6 million for Q1 2026 at Zymeworks, down from $268.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $493.0 million in Q4 2022 to a low of $163.6 million in Q1 2026.
• A 5-year average of $350.0 million and a median of $338.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 136.06% in 2023 and slumped 49.66% in 2026, its largest moves.
• Zymeworks' Common Equity stood at $493.0 million in 2022, then slipped by 5.71% to $464.8 million in 2023, then dropped by 27.12% to $338.8 million in 2024, then slipped by 20.74% to $268.5 million in 2025, then plunged by 39.07% to $163.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $163.6 million, $268.5 million, and $320.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison